



ASX ANNOUNCEMENT

26 March 2020

CardieX Announces Additional Contract with Pharmaceutical Giant, Bayer AG.

CardieX Limited (ASX: CDX) (CardieX, the Company) is pleased to announce that global pharmaceutical company Bayer AG and CardieX subsidiary ATCOR Medical have this week entered into an Amended Agreement for both the lease of ATCOR devices and provision of expanded data management services.

ATCOR's XCEL device is the only FDA cleared device for measuring the central aortic waveform and reporting on associated clinical data in adult subjects. XCEL is used by clinicians, research institutions, and pharmaceutical companies in monitoring critical hemodynamic data during patient treatment and drug trials in multiple clinical settings and for multiple disease states.

Bayer (OTCMKTS: BAYZF: \$USD15b) originally contracted ATCOR in December 2017 to provide clinical services and devices with a contract value of \$USD756,000. The total value of that contract and ongoing trial has now been increased under the Amended Agreement to \$USD1.53M **including this week's increase in contract value by an additional \$USD251K.**

This **second increase** in contract value with Bayer in the last month is consistent with recent announcements by CardieX that we were expecting further amendments in respect of **additional existing trials as well as new trial contracts** in the immediate future – together adding significant new incremental revenue to the Company for 2020 and 2021.

This new contract is also testament to the continued operations and ongoing business development success of the Company as we continue to move through this difficult economic period.

Craig Cooper
CEO & Managing Director

Authorised for release by:

Jarrold White
Company Secretary & Group Chief Financial Officer

For more information please contact:

Investor Relations
Peter Taylor
peter@nwrcommunications.com.au



About CardieX

CardieX is a global health technology company that develops digital and device-based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related disorders.

CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.

In September 2019 CardieX signed a joint development agreement with Mobvoi Information Technology Co. Ltd (Google's official Wear OS partner in China) to jointly develop an ecosystem of "smart heart" and other consumer health applications for the Google Wear OS platform in China based on CardieX subsidiary, ATCOR, software and algorithms.